Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alain Matagne

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Epilepsia|June 3, 2009
Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetamRafal M Kaminski, Michel Gillard, Karine Leclercq, et al.
Epilepsia|February 28, 2016
Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatmentHenrik Klitgaard, Alain Matagne, Jean-Marie Nicolas, et al.
Epilepsia|December 15, 2015
Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of actionJean-Marie Nicolas, Jonas Hannestad, Daniel Holden, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Epilepsia|June 3, 2009
Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetamRafal M Kaminski, Michel Gillard, Karine Leclercq, et al.
Epilepsia|February 28, 2016
Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatmentHenrik Klitgaard, Alain Matagne, Jean-Marie Nicolas, et al.
Epilepsia|December 15, 2015
Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of actionJean-Marie Nicolas, Jonas Hannestad, Daniel Holden, et al.
Pageof 3